The first program to utilise Alnylam's proprietary C16-siRNA technology was ALN-APP (NCT05231785),17 in collaboration with Regeneron, designed to target amyloid precursor protein (APP) for the potential treatment of Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA). Here, APP is linked to early-onset autosomal dominant Alzheimer disease.